SCHEMBL6426459

SCHEMBL6426459

O=C1N=C(NC2CC3C=CC2C3)SC1CCN1C(=O)c2ccccc2C1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.36
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
LMNA P02545 3/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
KDM1A O60341 1/20 0.32
USP2 O75604 1/20 0.32
RXFP1 Q9HBX9 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
MEN1 O00255 1/20 0.31
POLB P06746 1/20 0.31
MAPT P10636 1/20 0.31
KMT2A Q03164 1/20 0.31
GLS O94925 1/20 0.31
CREBBP Q92793 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6427053 0.90 NPSR1 (0.32) TSHRMAPK1ALDH1A1USP2POLB
SCHEMBL6428746 0.77 EPHX2 (0.33) ALDH1A1
SCHEMBL6510626 0.75 TDP1 (0.34) LMNAMAPK1ALDH1A1HPGDSMN1; SMN2
SCHEMBL6427696 0.75 DPP8 (0.34) TSHRALDH1A1
SCHEMBL6427367 0.74 MAPT (0.37) LMNATSHRALDH1A1MAPT
SCHEMBL6499622 0.72 HPGD (0.35) LMNAL3MBTL1ALDH1A1HPGDUSP2
SCHEMBL6427691 0.72 ALDH1A1 (0.33) LMNATSHRALDH1A1HPGDUSP2
SCHEMBL6426304 0.71 EPHX2 (0.34) L3MBTL1TSHRALDH1A1USP2MEN1
SCHEMBL6504880 0.71 TSHR (0.42) CYP2C19L3MBTL1TSHRALDH1A1MEN1
SCHEMBL14344793 0.71 TSHR (0.42) CYP2C19L3MBTL1TSHRALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050239853-A1 New compounds BIOVITRUM AB (SE) 2005-10-27 US claimed
WO-2005075471-A2 THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS BIOVITRUM AB (SE) 2005-08-18 WO claimed
US-20050239853-A1 New compounds BIOVITRUM AB (SE) 2005-10-27 US disclosed
WO-2005075471-A2 THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS BIOVITRUM AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239853-A1 New compounds HSD11B1, CYP11B1, HSD3B1 ACHE 1253/4885CYP1A2 48/4885CYP2C9 133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.